Launch Costs—Spend Wisely: Pre-Launch and Post-Launch Analysis

Apr 22, 2020

By Dean Giovanniello, Vice President (Health Advances LLC)

Posted by Health Advances LLC

Launch Costs—Spend Wisely: Pre-Launch and Post-Launch Analysis

By Dean Giovanniello, Vice President (Health Advances LLC)

Estimating the cost of a new product launch must take into account all expenses pre- and post-launch, in addition to the launch year, in order to fully capture the extent of the financial investment. In our most recent white paper, Launch Costs—Spend Wisely: First-In-Class and Follow-On Launch Cost Analysis, we showed that a company may spend between $475MM and $830MM in a six-year period, including all investments made immediately preceding and following a drug launch.

Our previous study in July 2018, Launch Excellence: Once in a Life Cycle Opportunity, showed that single-product pharmaceutical companies spend an average of ~$125MM in the three years prior to launch. In this analysis, we extended the review period by three years: we assessed four single-product pharmaceutical companies, in both orphan and non-orphan indications, and evaluated their spending three years prior to launch, the launch year, and two years after the launch year, for a total of six years.

Distribution of Launch Spending for Profiled Analogs
Good financial plans reflect strong strategies that go above and beyond the launch year itself. Launch planning is a comprehensive exercise that includes market and competitive analysis, thoughtful strategy, focused tactical plans, and realistic financial and resource allocation. The profiled analogs show that competition level and callpoint type are significant determinants of launch costs and resource requirements. In successful launches, all of these pieces should be evaluated and support each other.

About the Author

Dean Giovanniello, a Vice President based in the Health Advances Newton office. He is a co-leader of the Health Advances Biopharma Launch Excellence practice and focuses on launch and brand strategy, business development (i.e., partnering, licensing and M&A strategy), commercial due diligence, market assessments, forecasting, and financial modeling. For further discussion of these topics, contact Dean at


About Health Advances Biopharma Launch Excellence Practice

Health Advances Biopharma Launch Excellence Practice has unique capabilities to provide launch strategy and planning services founded on actionable, nuanced market insights and flexible launch planning solutions.

For more information, please visit


Health Advances Biopharma Thought Leadership

We are active industry participants committed to providing detailed perspectives and insights on key topics of interest within biopharma. Following is a sample of relevant content authored by our team:

See all Member News